Clinical Trials Logo

Leukemia, Myeloid, Chronic-Phase clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic-Phase.

Filter by:

NCT ID: NCT00320190 Terminated - Clinical trials for Leukemia, Myeloid, Chronic

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy of dasatinib with that of high-dose (800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved only a suboptimal response after at least 3 months of monotherapy with 400-mg imatinib. The safety of these treatments will also be evaluated.

NCT ID: NCT00124748 Terminated - Clinical trials for Leukemia, Myeloid, Chronic Phase

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

TOPS
Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.

NCT ID: NCT00114959 Terminated - Clinical trials for Myeloid Leukemia, Chronic

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine may restore a response to Gleevec or the combined treatment may promote a better response than using Gleevec alone.

NCT ID: NCT00101088 Terminated - Clinical trials for Relapsing Chronic Myelogenous Leukemia

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Start date: April 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given with imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus with imatinib mesylate may kill more cancer cells

NCT ID: NCT00038649 Terminated - Clinical trials for Myelogenous Leukemia, Chronic, Chronic Phase

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Start date: June 2001
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to see if higher doses of imatinib mesylate (Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.

NCT ID: NCT00003561 Terminated - Leukemia Clinical Trials

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Start date: February 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of therapy. Combining sargramostim with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who are receiving interferon alfa for chronic phase chronic myelogenous leukemia that is in remission.